FI952179A - Uusia 3,3-difenyylipropyyliamiineja, niiden käyttö ja valmistus - Google Patents

Uusia 3,3-difenyylipropyyliamiineja, niiden käyttö ja valmistus Download PDF

Info

Publication number
FI952179A
FI952179A FI952179A FI952179A FI952179A FI 952179 A FI952179 A FI 952179A FI 952179 A FI952179 A FI 952179A FI 952179 A FI952179 A FI 952179A FI 952179 A FI952179 A FI 952179A
Authority
FI
Finland
Prior art keywords
compounds
diphenylpropylamines
methyl
preparation
formula
Prior art date
Application number
FI952179A
Other languages
English (en)
Swedish (sv)
Other versions
FI952179A0 (fi
FI120256B (fi
Inventor
Rolf Arne Johansson
Pinchas Moses
Lisbeth Nilverbant
Bengt Aake Sparf
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20387730&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI952179(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of FI952179A0 publication Critical patent/FI952179A0/fi
Publication of FI952179A publication Critical patent/FI952179A/fi
Application granted granted Critical
Publication of FI120256B publication Critical patent/FI120256B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Luminescent Compositions (AREA)
  • Photoreceptors In Electrophotography (AREA)
FI952179A 1992-11-06 1995-05-05 Menetelmä uusien terapeuttisesti aktiivisten 3,3-difenyylipropyyliamiinien valmistamiseksi ja välituotteita FI120256B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE9203318A SE9203318D0 (sv) 1992-11-06 1992-11-06 Novel 3,3-diphenylpropylamines, their use and preparation
SE9203318 1992-11-06
SE9300927 1993-11-05
PCT/SE1993/000927 WO1994011337A1 (en) 1992-11-06 1993-11-05 Novel 3,3-diphenylpropylamines, their use and preparation

Publications (3)

Publication Number Publication Date
FI952179A0 FI952179A0 (fi) 1995-05-05
FI952179A true FI952179A (fi) 1995-05-05
FI120256B FI120256B (fi) 2009-08-31

Family

ID=20387730

Family Applications (1)

Application Number Title Priority Date Filing Date
FI952179A FI120256B (fi) 1992-11-06 1995-05-05 Menetelmä uusien terapeuttisesti aktiivisten 3,3-difenyylipropyyliamiinien valmistamiseksi ja välituotteita

Country Status (15)

Country Link
US (4) USRE40851E1 (fi)
EP (1) EP0667852B1 (fi)
JP (1) JP3343256B2 (fi)
AT (1) ATE164828T1 (fi)
AU (1) AU672458B2 (fi)
CA (1) CA2148827C (fi)
DE (1) DE69317898T2 (fi)
DK (1) DK0667852T3 (fi)
ES (1) ES2117155T3 (fi)
FI (1) FI120256B (fi)
HK (1) HK1006349A1 (fi)
HU (1) HU224916B1 (fi)
NO (1) NO305477B1 (fi)
SE (1) SE9203318D0 (fi)
WO (1) WO1994011337A1 (fi)

Families Citing this family (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9203318D0 (sv) * 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
WO1998000140A1 (en) * 1996-07-01 1998-01-08 Sepracor, Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (r)-trihexyphenidyl
EP0948964B1 (en) * 1996-12-02 2003-04-02 Kyorin Pharmaceutical Co., Ltd. Novel n-substituted pyrrolidine derivatives and process for preparing the same
SE9701144D0 (sv) * 1997-03-27 1997-03-27 Pharmacia & Upjohn Ab Novel compounds, their use and preparation
EP0957073A1 (en) * 1998-05-12 1999-11-17 Schwarz Pharma Ag Novel derivatives of 3,3-diphenylpropylamines
PT1039882E (pt) 1998-08-27 2011-01-03 Pfizer Health Ab Formulação terapêutica para administrar tolterodina com libertação controlada
SK6412002A3 (en) 1999-11-11 2002-09-10 Pharmacia Ab Pharmaceutical formulation containing tolterodine and its use
DE19955190A1 (de) * 1999-11-16 2001-06-21 Sanol Arznei Schwarz Gmbh Stabile Salze neuartiger Derivate von 3,3-Diphenylpropylaminen
SE9904850D0 (sv) * 1999-12-30 1999-12-30 Pharmacia & Upjohn Ab Novel process and intermediates
WO2001070689A1 (fr) 2000-03-24 2001-09-27 Meiji Seika Kaisha, Ltd. DERIVES DE LA DIPHENYLALKYLAMINE UTILES COMME AGONISTES DU RECEPTEUR DE L'OPIOIDE $g(d)
DE10028443C1 (de) * 2000-06-14 2002-05-29 Sanol Arznei Schwarz Gmbh Verfahren zur Herstellung von 3,3-Diarylpropylaminen, (R,S)- und (R)-4-Phenyl-2-chromanon-6-carbonsäure sowie (R)-4-Phenyl-2-chromanon-carbonsäure-cinchonidinsalz und deren Verwendung zur Herstellung eines rechtsdrehenden Hydroxybenzylalkohols und von pharmazeutischen Zusammensetzungen
DE10033016A1 (de) 2000-07-07 2002-01-24 Sanol Arznei Schwarz Gmbh Verfahren zur Herstellung von 3,3-Diarylpropylaminen
PE20020547A1 (es) 2000-10-24 2002-06-12 Upjohn Co Uso de la tolterodina en tratamientos del asma
NZ528377A (en) * 2001-03-27 2005-05-27 Galen Chemicals Ltd Intravaginal drug delivery devices for the administration of an antimicrobial agent
US20030027856A1 (en) * 2001-06-29 2003-02-06 Aberg A.K. Gunnar Tolterodine metabolites
US20030060513A1 (en) * 2001-09-27 2003-03-27 Arneric Stephen P. Pharmaceutical composition
MXPA04003865A (es) * 2001-10-26 2004-07-08 Upjohn Co Compuestos de amonio cuaternario y sus usos como agentes antimuscarinicos.
JP2005511582A (ja) * 2001-11-05 2005-04-28 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー 抗ムスカリン・エアゾール
WO2003039524A1 (en) * 2001-11-09 2003-05-15 Pharmacia Ab Anti-muscarinic agent and estrogen-agonist for treating unstable or overactive bladder
WO2003053428A1 (en) * 2001-12-20 2003-07-03 Pharmacia Corporation Controlled release dosage form having improved drug release properties
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
US7005449B2 (en) 2002-04-23 2006-02-28 Pharmacia & Upjohn Company Tolterodine salts
CN1668585A (zh) * 2002-07-08 2005-09-14 兰贝克赛实验室有限公司 用作蝇蕈碱受体拮抗剂的3,6－二取代氮杂双环[3.1.0]己烷衍生物
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
US7838527B2 (en) * 2002-11-13 2010-11-23 Novartis Vaccines And Diagnostics, Inc. Methods of treating cancer and related methods
DE10315917A1 (de) * 2003-04-08 2004-11-18 Schwarz Pharma Ag Hochreine Basen von 3,3-Diphenylpropylaminmonoestern
AU2003214520A1 (en) * 2003-04-09 2004-11-01 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
WO2004089900A1 (en) * 2003-04-11 2004-10-21 Ranbaxy Laboratories Limited Azabicyclo derivatives as muscarinic receptor antagonists
BRPI0409653A (pt) 2003-04-25 2006-04-25 Pharmacia & Upjohn Co Llc 3,3-difenilpropilaminas (tolterodina) substituìdas com halogênio com atividade antimuscarìnica
WO2004105692A2 (en) * 2003-05-23 2004-12-09 Bridge Pharma, Inc. Smooth muscle spasmolytic agents
WO2005012227A2 (en) * 2003-08-05 2005-02-10 Ranbaxy Laboratories Limited Process for preparation of 2-(3-diisopropylamino-1-phenylpropyl)-4-hydroxymethyl-phenol, a metabolite of tolterodine
ES2235648B1 (es) * 2003-12-22 2006-11-01 Ragactives, S.L. Procedimiento para la obtencion de tolterodina.
EP1701932B1 (en) * 2003-12-24 2012-07-18 Cipla Ltd. Tolterodine, compositions and uses thereof, and preparation of the same
US7875624B2 (en) 2004-02-20 2011-01-25 Novartis Vaccines And Diagnostics, Inc. Modulating and measuring cellular adhesion
EP1629834A1 (en) 2004-08-27 2006-03-01 KRKA, D.D., Novo Mesto Sustained release pharmaceutical composition of tolterodine
US20100035954A1 (en) * 2004-12-15 2010-02-11 Mohammad Salman Acid addition salts of muscarinic receptor antagonists
TW200637804A (en) * 2005-01-10 2006-11-01 Teva Pharma Substantially pure tolterodine tartrate and process for preparing thereof
WO2006117754A1 (en) * 2005-05-03 2006-11-09 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0] hexane derivatives as muscarinic receptor antagonists
KR101319122B1 (ko) 2005-05-13 2013-10-23 노파르티스 아게 약물 저항성 암을 치료하는 방법
AU2006327882A1 (en) * 2005-12-20 2007-06-28 Pfizer Products Inc. Pharmaceutical combination for the treatment of LUTS comprising a PDE5 inhibitor and a muscarinic antagonist
MX2008011963A (es) 2006-03-20 2008-10-01 Pfizer Ltd Derivados de amina.
CN101454273B (zh) * 2006-05-31 2013-08-21 施瓦茨制药有限公司 取代的羟甲基苯酚的合成方法
EP1862449A1 (en) * 2006-05-31 2007-12-05 Schwarz Pharma Ltd. A shortened synthesis of substituted hydroxymethyl phenols
IES20060424A2 (en) * 2006-06-08 2007-10-31 Schwarz Pharma Ltd Accelerated synthesis of (3-Diisopropylamino-1-phenylpropyl)-4-(hydroxymethyl)phenol and its phenolic monoesters
CA2648333C (en) 2006-06-09 2014-04-29 Schwarz Pharma Ltd Synthesis of phenolic esters of hydroxymethyl phenols
KR101488740B1 (ko) 2006-06-12 2015-02-03 유씨비 파마 게엠베하 새로운 키랄 중간체, 그 키랄 중간체의 제조방법 및 톨테로딘, 페소테로딘 또는 그 활성대사물질의 제조에서 그키랄 중간체의 사용
IES20060435A2 (en) 2006-06-12 2007-12-12 Schwarz Pharma Ltd Shortened synthesis using paraformaldehyde or trioxane
EP2044001B1 (en) * 2006-06-20 2016-11-23 LEK Pharmaceuticals d.d. Process for preparation of 3-(2-hydroxy-5-substituted phenyl)-n-alkyl-3-phenylpropylamines
WO2009037569A2 (en) * 2007-09-21 2009-03-26 Actavis Group Ptc Ehf An improved process for the preparation of fesoterodine
KR101188333B1 (ko) * 2008-02-20 2012-10-09 에스케이케미칼주식회사 안정성이 우수하고 경피제로 유용한 톨테로딘 결정성산부가염
US20090214665A1 (en) * 2008-02-26 2009-08-27 Lai Felix S Controlled Release Muscarinic Receptor Antagonist Formulation
KR20120014583A (ko) * 2009-05-11 2012-02-17 라티오팜 게엠베하 타르타르산 염 형태의 데스페소테로딘
IT1394217B1 (it) 2009-05-15 2012-06-01 Chemi Spa Metodo di preparazione di fesoterodina e/o fesoterodina fumarato.
IT1394219B1 (it) 2009-05-15 2012-06-01 Chemi Spa Metodo di preparazione di fesoterodina fumarato di elevata purezza.
ES2456866T3 (es) * 2009-07-27 2014-04-23 Crystal Pharma, S.A.U. Procedimiento para la obtención de 3,3-difenilpropilaminas
IT1396373B1 (it) 2009-10-29 2012-11-19 Dipharma Francis Srl Procedimento per la preparazione di fesoterodina.
IL210279A0 (en) 2009-12-25 2011-03-31 Dexcel Pharma Technologies Ltd Extended release compositions for high solubility, high permeability acdtive pharmaceutical ingredients
EP2364966A1 (en) 2010-03-09 2011-09-14 LEK Pharmaceuticals d.d. Process for preparation of 3-(2-hydroxy-5-substituted phenyl)-3-phenylpropylamines, intermediates for making hydroxytolterodine
US20110282094A1 (en) 2010-05-11 2011-11-17 Intas Pharmaceuticals Limited Process for preparation of phenolic monoesters of hydroxymethyl phenols
WO2011145019A1 (en) * 2010-05-17 2011-11-24 Orchid Chemicals And Pharmaceuticals Limited Improved process for diphenylpropylamine derivatives
IT1401451B1 (it) 2010-06-10 2013-07-26 Chemi Spa Nuovo processo di preparazione di 2-idrossi-4-fenil-3,4-diidro-2h-cromen-6-il-metanolo e (r)-2-[3-(diisopropilammino)-1-fenilpropil]-4-(idrossimetil)fenolo.
IT1403094B1 (it) 2010-12-09 2013-10-04 Dipharma Francis Srl Procedimento per la preparazione di fesoterodina o un suo sale
TWI590821B (zh) 2011-01-18 2017-07-11 輝瑞有限公司 固體分子分散液
US9422228B2 (en) 2012-05-04 2016-08-23 Crystal Pharma, S.A.U. Process for the preparation of optically pure fesoterodine derivatives
CA2875342C (en) 2012-06-14 2017-06-13 Ratiopharm Gmbh Desfesoterodine salts
ITMI20121232A1 (it) 2012-07-16 2014-01-17 Cambrex Profarmaco Milano Srl Procedimento per la preparazione di 2-(3-n,n-diisopropilamino-1-fenilpropil)-4-idrossimetil-fenolo e suoi derivati
GB201402556D0 (en) 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles
WO2016148444A1 (ko) * 2015-03-17 2016-09-22 제이더블유중외제약 주식회사 신규 데스페소테로딘 유도체, 이의 약제학적으로 허용되는 염 및 이를 포함하는 약제학적 조성물
WO2017137955A1 (en) 2016-02-14 2017-08-17 Celestis Pharmaceuticals Pvt. Ltd. Novel (r) and rac 3-(2-(allyloxy)-5-methylphenyl)-n,n-diisopropyl-3- phenylpropan-1-amine and its use for synthesis of (r) and rac-2-(3- (diisopropylamino)-1-phenylpropyl)-4-(hydroxymethyl)phenol
CN110372571B (zh) 2018-04-12 2022-11-15 中国科学院大连化学物理研究所 一种2-(2,2-二芳基乙基)-环胺衍生物或盐及合成和应用与组合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK111894A (fi) 1962-11-15
GB1169944A (en) * 1966-08-25 1969-11-05 Geistlich Soehne Ag Novel 3,3-Diphenylpropylamines and processes for the preparation thereof
GB1169945A (en) 1966-08-25 1969-11-05 Geistlich Soehne Ag Pharmaceutical Compositions containing Diphenylalkyl-amine Derivatives
US4139537A (en) 1976-06-29 1979-02-13 Cooper Laboratories, Inc. 3-Aryloxy-1-(2- or 4-iminodihydro-1-pyridyl)-2-propanol antiarrhythmic compounds
SE8800207D0 (sv) 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
US5382600A (en) * 1988-01-22 1995-01-17 Pharmacia Aktiebolag 3,3-diphenylpropylamines and pharmaceutical compositions thereof
SE9203318D0 (sv) * 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
US5472958A (en) * 1994-08-29 1995-12-05 Abbott Laboratories 2-((nitro)phenoxymethyl) heterocyclic compounds that enhance cognitive function
PE20020547A1 (es) * 2000-10-24 2002-06-12 Upjohn Co Uso de la tolterodina en tratamientos del asma

Also Published As

Publication number Publication date
NO305477B1 (no) 1999-06-07
HU9501329D0 (en) 1995-06-28
DE69317898D1 (de) 1998-05-14
AU5438094A (en) 1994-06-08
NO951775L (no) 1995-05-05
AU672458B2 (en) 1996-10-03
DK0667852T3 (da) 1999-01-11
EP0667852A1 (en) 1995-08-23
HUT72742A (en) 1996-05-28
FI952179A0 (fi) 1995-05-05
US5686464A (en) 1997-11-11
HK1006349A1 (en) 1999-02-19
CA2148827C (en) 2005-01-04
EP0667852B1 (en) 1998-04-08
HU224916B1 (en) 2006-04-28
CA2148827A1 (en) 1994-05-26
ES2117155T3 (es) 1998-08-01
JP3343256B2 (ja) 2002-11-11
US5559269A (en) 1996-09-24
NO951775D0 (no) 1995-05-05
DE69317898T2 (de) 1998-10-15
JPH08503208A (ja) 1996-04-09
SE9203318D0 (sv) 1992-11-06
USRE40851E1 (en) 2009-07-14
WO1994011337A1 (en) 1994-05-26
FI120256B (fi) 2009-08-31
USRE39667E1 (en) 2007-05-29
ATE164828T1 (de) 1998-04-15

Similar Documents

Publication Publication Date Title
FI952179A (fi) Uusia 3,3-difenyylipropyyliamiineja, niiden käyttö ja valmistus
FI903688A0 (fi) Nya aminer, deras anvaendning och framstaellning.
ZA932168B (en) Naphthylalkylamines, process for preparing them and pharmaceutical compositions containing them
ZA936658B (en) Benzopyran compounds process for their preparation and the pharmaceutical compositions which contain them
CA2085796A1 (en) 3(2h)-pyridazinone derivatives and process for the preparation thereof
AU668398B2 (en) New aminoalkylchromones, processes for the preparation thereof, and pharmaceutical compositions containing them
AU659738B2 (en) New pyrrolothienopyrazine compounds, processes for the preparation thereof, and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 120256

Country of ref document: FI

MA Patent expired